成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 147118-37-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 147118-37-4
Chemical Structure| 147118-37-4
Structure of 147118-37-4 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 147118-37-4 ]

Related Doc. of [ 147118-37-4 ]

Alternatived Products of [ 147118-37-4 ]
Product Citations

Product Details of [ 147118-37-4 ]

CAS No. :147118-37-4 MDL No. :MFCD08458342
Formula : C16H18FN3O3S Boiling Point : No data available
Linear Structure Formula :- InChI Key :WOCOTUDOVSLFOB-UHFFFAOYSA-N
M.W : 351.40 Pubchem ID :10473133
Synonyms :

Calculated chemistry of [ 147118-37-4 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 24
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.31
Num. rotatable bonds : 5
Num. H-bond acceptors : 6.0
Num. H-bond donors : 0.0
Molar Refractivity : 90.56
TPSA : 88.61 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.97 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.22
Log Po/w (XLOGP3) : 2.07
Log Po/w (WLOGP) : 4.12
Log Po/w (MLOGP) : 0.8
Log Po/w (SILICOS-IT) : 2.56
Consensus Log Po/w : 2.35

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.36
Solubility : 0.152 mg/ml ; 0.000434 mol/l
Class : Soluble
Log S (Ali) : -3.56
Solubility : 0.0968 mg/ml ; 0.000275 mol/l
Class : Soluble
Log S (SILICOS-IT) : -5.22
Solubility : 0.00214 mg/ml ; 0.00000608 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.91

Safety of [ 147118-37-4 ]

Signal Word:Warning Class:
Precautionary Statements:P261-P305+P351+P338 UN#:
Hazard Statements:H302-H315-H319-H335 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 147118-37-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 147118-37-4 ]
  • Downstream synthetic route of [ 147118-37-4 ]

[ 147118-37-4 ] Synthesis Path-Upstream   1~3

  • 1
  • [ 380460-37-7 ]
  • [ 147118-37-4 ]
  • [ 289042-12-2 ]
YieldReaction ConditionsOperation in experiment
91% With potassium <i>tert</i>-butylate In tetrahydrofuran; water at -15 - 42℃; for 1 h; Inert atmosphere The present embodiment of rosuvastatin calcium intermediate preparation,which is 6 - [(1E) -2- [4- (4- fluorophenyl) -6-isopropyl- 2- [methyl (methylsulfonyl) amino] -5-pyrimidinyl] ethenyl] -dimethyl-l, 3-dioxane-4-acetic acid tert-butyl ester comprises the following steps: (1) under the protection of N2,To a 1000 mL reaction flask was added 36 g of compound of formula 3,21 g of compound of formula 2 and 620 mL of tetrahydrofuran,Heated to 42 ° C and stirred until clear,Then cooled to -15 ° C, added 1.8mL of water, 20g of potassium tert-butoxide, the reaction was incubated for 60 minutes after the addition; (2) The reaction was quenched with 105mL saturated ammonium chloride, quenched after the addition of 600mL water, and then 600mL ethyl acetate extraction, washed with brine, dried and concentrated to give a pale yellow solid,Add 288mL of methanol and 48mL water recrystallization,Filtration and drying gave 31 g of a white solid, which was the target product.
120 g With sodium hydride In tetrahydrofuran at 0 - 35℃; To a solution of N-[4-(4-fluoro-phenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-N- methyl-methane sulfonamide (100 gms) and compound III (wherein Rl=l-phenyl-lH- tetrazol-5-yl, X=0 and R2= tert-butyl; 130 gms) in tetrahydrofuran (2000 mL) was added sodium hydride (34 gms) lot wise at 0°C to 5°C. The reaction mass was stirred for 30 min at 0°C to 5°C and then the temperature was gradually allowed to raise to 25 °C to 35 °C and stirred till reaction completion. The reaction mass was quenched with 10percent potassium carbonate solution (lOOOmL) and extracted with ethyl acetate. The organic layer was washed with 10 percent NaCl solution and concentrated under vacuum. The obtained residue was triturated with methanol (500mL) ; the precipitated white solid was filtered and dried at 55°C to afford 120 gms of the title compound. HPLC purity: >98percent and Z-isomer content: <0.2percent.
Reference: [1] Patent: CN107298675, 2017, A, . Location in patent: Paragraph 0023-0026; 0027-0030; 0031-0034
[2] Patent: WO2016/125086, 2016, A1, . Location in patent: Page/Page column 26-27
  • 2
  • [ 1054627-26-7 ]
  • [ 147118-37-4 ]
  • [ 289042-12-2 ]
YieldReaction ConditionsOperation in experiment
64% With sodium hexamethyldisilazane In tetrahydrofuran at -75 - -10℃; for 2 h; Example 6b Using NaHMDS N-(4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (0.5 g, 1.4 mmol) and 2-((4 ,6S)-6-((benzo[d]thiazol-2-ylsulfonyl)methyl)-2,2-dimethyl- 1 ,3-dioxan-4-yl)acetate te/f-butyl ester (0.7 g, 1.6 mmol) were added to 10 mL of dry THF. After stirring for 10 min at 20°C, the reaction mixture was cooled to -70°C. At this temperature 1.9 mL of NaHMDS solution (1 M in THF, total 3.8 mmol) was added in 60 min keeping the temperature between -70 and -75°C. When dosing was completed, the temperature of the reaction mixture was allowed to increase to -10°C. After stirring at this temperature for 1 h, the reaction was quenched with 10percent aqueous NaHC03 (5 mL). The phases were separated. The aqueous layer was extracted with 2 x 20 mL of ethyl acetate. The combined organic phases were washed with 5percent aqueous Na2C03 and concentrated under vacuum. H PLC analysis indicated an E to Z ratio of >99: 1 . The residue was crystallized from methanol to give 2-((4f?,6S)-6-((E)-2-(4-(4-fluorophenyl)-6- isopropyl-2-(N-methylmethylsulfonamido) pyrimidin-5-yl)vinyl)-2,2-dimethyl-1 ,3-dioxan- 4-yl)acetate, te/f-butyl ester as a solid (0.52 g, 0.9 mmol, 64percent yield).
65 g With potassium <i>tert</i>-butylate In tetrahydrofuran at -80 - 45℃; for 1.75 h; EXAMPLE-6PREPARATION OF tert-BUTYL 2-[(4R,6-2,2-DIMETIIYL-6-[(E)-2-[4-(4- FLUOROPHENYL)-6-ISOPROPYL-2-[N-METHYL(N-METHYLSULFONYL)-AMINOIPYRIMIDIN-5-YL]VINYLI-1,3-DIOXAN-4-YLIACETATE [DIPROTECTED ROSUVASTATIN)A mixture of 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl arnino)pyrimidine-5-ylcarboxaldehyde (50 g, 0.142 mole) and chiral diol sulphone (62.82 g, 0.142 mole) was dissolved in tetrahydrofuran (750 ml) at 40-45°C. The above reaction mass was cooled to -75 to -80°C and thereafter potassium tertbutoxide (22.33 g, 0.199 mole) was dissolved in tetrahydrofuran (100 ml) slowly at -80°C to -75°C over a period of 45 mi Stirring was continued till pyrimidine carboxaldehyde was consumed (—1 h) and the progress of reaction was monitored by HPLC. After completion of the reaction, 20percent aqueous ammonium chloride solution (500 ml) was added to the reaction mass at -75° to -80°C. Thereafter, temperature was raised to 20-30°C. The product was extracted with ethyl acetate (2 x 250 ml), washed with 10percent w/w aqueous sodium chloride (500 ml) and solvent was evaporated under reduced pressure at 40-45°C. Thereafter, methanol (750 ml) was added to the concentrated mass and heated to 60-65°C to obtain a clear solution. It was cooled to 0-5°C and the title compound was isolated by filtration.Yield: 65 gChroinatographic Purity (by HPLC): 99percent
Reference: [1] Patent: WO2012/98048, 2012, A1, . Location in patent: Page/Page column 18-19
[2] Patent: WO2014/108795, 2014, A2, . Location in patent: Page/Page column 17
[3] Patent: WO2016/125086, 2016, A1, . Location in patent: Page/Page column 28
  • 3
  • [ 1054627-26-7 ]
  • [ 147118-37-4 ]
  • [ 289042-12-2 ]
YieldReaction ConditionsOperation in experiment
52% With lithium hexamethyldisilazane In tetrahydrofuran at -75 - -10℃; for 2.33333 h; Example 6 Preparation of 2-((4 ?,6S)-6-((E)-2-(4-(4-fluorophenyl)-6-isopropyl-2-(N- methylmethylsulfonamido)pyrimidin-5-yl)vinyl)-2,2-dimethyl-1 ,3-dioxan-4- yl)acetate, ferf-butyl ester (P) from N-(4-(4-fluorophenyl)-5-formyl-6- isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (J) and 2-((4 ?,6S)-6- ((benzo[d]thiazol-2-ylsulfonyl)methyl)-2,2-dimethyl-1 ,3-dioxan-4-yl)acetate ferf- (E) (J) (P)Example 6a Using Li HMDS N-(4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfon ( J , 1 . 0 g, 2.9 mmol) and 2-((4ft,6S)-6-((benzo[d]thiazol-2-ylsulfonyl)methyl)-2,2- dimethyl-1 ,3-dioxan-4-yl)acetate te/f-butyl ester (E, 1.4 g, 3.1 mmol) were added to dry THF (12 mL). After stirring for 10 min at 20°C, the reaction mixture was cooled to -70°C and 3.8 mL of Li HM DS solution (1 M in TH F, total 3.8 mmol) was added in 80 min keeping the temperature between -70 and -75°C. When dosing was completed, the temperature of the reaction mixture was allowed to increase to -10°C. After stirring at this temperature for 1 h, the reaction was quenched with 10percent aqueous NaHC03 (5 mL). The phases were separated. The aqueous layer was extracted with 2 x 20 mL of ethyl acetate. The combined organic phases were washed with 5percent aqueous Na2C03 and concentrated under vacuum. H PLC analysis indicated an E to Z ratio of 70:30. The residue was crystallized from methanol to give 2-((4f?,6S)-6-((E)-2-(4-(4-fluorophenyl)-6- isopropyl-2-(N-methylmethylsulfonamido) pyrimidin-5-yl)vinyl)-2,2-dimethyl-1 ,3-dioxan- 4-yl)acetate, te/f-butyl ester as a solid (P, 0.87 g, 1.5 mmol, 52percent yield).
Reference: [1] Patent: WO2012/98048, 2012, A1, . Location in patent: Page/Page column 17-18
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 147118-37-4 ]

Fluorinated Building Blocks

Chemical Structure| 799842-07-2

[ 799842-07-2 ]

N-[5-Bromomethyl-4-(4-fluorophenyl)-6-isopropylpyrimidine-2-yl]-N-methylmethane sulfonamide

Similarity: 0.90

Chemical Structure| 147118-36-3

[ 147118-36-3 ]

4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsufonyl)amino]pyrimidine-5-yl-methanol

Similarity: 0.88

Chemical Structure| 147118-30-7

[ 147118-30-7 ]

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidine-5-carboxylate

Similarity: 0.87

Chemical Structure| 147098-18-8

[ 147098-18-8 ]

Sodium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate

Similarity: 0.86

Chemical Structure| 147118-39-6

[ 147118-39-6 ]

5-Oxorosuvastatin methyl ester

Similarity: 0.85

Aryls

Chemical Structure| 799842-07-2

[ 799842-07-2 ]

N-[5-Bromomethyl-4-(4-fluorophenyl)-6-isopropylpyrimidine-2-yl]-N-methylmethane sulfonamide

Similarity: 0.90

Chemical Structure| 147118-36-3

[ 147118-36-3 ]

4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsufonyl)amino]pyrimidine-5-yl-methanol

Similarity: 0.88

Chemical Structure| 147118-30-7

[ 147118-30-7 ]

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidine-5-carboxylate

Similarity: 0.87

Chemical Structure| 147098-18-8

[ 147098-18-8 ]

Sodium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate

Similarity: 0.86

Chemical Structure| 147118-39-6

[ 147118-39-6 ]

5-Oxorosuvastatin methyl ester

Similarity: 0.85

Aldehydes

Chemical Structure| 121660-37-5

[ 121660-37-5 ]

2-Cyclopropyl-4-(4-fluorophenyl)quinoline-3-carbaldehyde

Similarity: 0.52

Amines

Chemical Structure| 799842-07-2

[ 799842-07-2 ]

N-[5-Bromomethyl-4-(4-fluorophenyl)-6-isopropylpyrimidine-2-yl]-N-methylmethane sulfonamide

Similarity: 0.90

Chemical Structure| 147118-36-3

[ 147118-36-3 ]

4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsufonyl)amino]pyrimidine-5-yl-methanol

Similarity: 0.88

Chemical Structure| 147118-30-7

[ 147118-30-7 ]

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidine-5-carboxylate

Similarity: 0.87

Chemical Structure| 147098-18-8

[ 147098-18-8 ]

Sodium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate

Similarity: 0.86

Chemical Structure| 147118-39-6

[ 147118-39-6 ]

5-Oxorosuvastatin methyl ester

Similarity: 0.85

Sulfamides

Chemical Structure| 799842-07-2

[ 799842-07-2 ]

N-[5-Bromomethyl-4-(4-fluorophenyl)-6-isopropylpyrimidine-2-yl]-N-methylmethane sulfonamide

Similarity: 0.90

Chemical Structure| 147118-36-3

[ 147118-36-3 ]

4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsufonyl)amino]pyrimidine-5-yl-methanol

Similarity: 0.88

Chemical Structure| 147118-30-7

[ 147118-30-7 ]

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidine-5-carboxylate

Similarity: 0.87

Chemical Structure| 147098-18-8

[ 147098-18-8 ]

Sodium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate

Similarity: 0.86

Chemical Structure| 147118-39-6

[ 147118-39-6 ]

5-Oxorosuvastatin methyl ester

Similarity: 0.85

Related Parent Nucleus of
[ 147118-37-4 ]

Pyrimidines

Chemical Structure| 799842-07-2

[ 799842-07-2 ]

N-[5-Bromomethyl-4-(4-fluorophenyl)-6-isopropylpyrimidine-2-yl]-N-methylmethane sulfonamide

Similarity: 0.90

Chemical Structure| 147118-36-3

[ 147118-36-3 ]

4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsufonyl)amino]pyrimidine-5-yl-methanol

Similarity: 0.88

Chemical Structure| 147118-30-7

[ 147118-30-7 ]

Ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidine-5-carboxylate

Similarity: 0.87

Chemical Structure| 147098-18-8

[ 147098-18-8 ]

Sodium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate

Similarity: 0.86

Chemical Structure| 147118-39-6

[ 147118-39-6 ]

5-Oxorosuvastatin methyl ester

Similarity: 0.85

; ;